STOCK TITAN

Enlivex Therapeutics Ltd. Ordinary Shares - ENLV STOCK NEWS

Welcome to our dedicated page for Enlivex Therapeutics Ltd. Ordinary Shares news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics Ltd. Ordinary Shares stock.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage immunotherapy company focused on developing innovative allogeneic drugs to rebalance the immune system. The company's flagship product candidate, Allocetra™, is under development for multiple severe and critical conditions.

Allocetra™ is currently in a Phase IIB clinical trial targeting patients with severe sepsis, a life-threatening condition caused by the body's response to infection. Additionally, it is being investigated in a Phase II clinical trial for the treatment of COVID-19 patients with severe and critical conditions. The company is also exploring Allocetra™ in a Phase IIA trial for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplants (HSCT).

Enlivex is advancing Allocetra™ as a potential treatment for complications associated with bone marrow transplants, acute multiple organ failure, and as a combination therapy with various anti-cancer treatments to enhance efficacy. The immunotherapy works by reprogramming macrophages to their homeostatic state, thus rebalancing the immune system.

Recently, the Israeli Ministry of Health authorized a new trial for Allocetra™ targeting osteoarthritis, a chronic inflammatory condition affecting millions worldwide. This multi-country, double-blind, placebo-controlled Phase I/II trial aims to evaluate the safety and efficacy of Allocetra™ injections in knee osteoarthritis patients.

The company has shown promising results in its Phase II study of Allocetra™ in sepsis patients, demonstrating a favorable safety profile and potential effectiveness. With approvals from the Danish Medicines Agency and other international regulators, Enlivex is extending its clinical trials across multiple countries to further evaluate Allocetra™'s broad therapeutic potential.

Rhea-AI Summary
Enlivex receives authorization from the Danish Regulatory Agency for Phase I/II Trial on Allocetra in Knee Osteoarthritis Patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics announced a conference call to discuss topline results from its Phase II trial of Allocetra™ in sepsis patients. The trial included 120 patients, with the leadership team presenting and a live Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.02%
Tags
conferences clinical trial
-
Rhea-AI Summary
Enlivex Therapeutics (ENLV) announces positive results from Phase II study of Allocetra™ in sepsis patients, showing significant reductions in SOFA scores and mortality rates. The study indicates a potential market opportunity for Allocetra™ in high-risk sepsis patients originating from urinary tract infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.02%
Tags
Rhea-AI Summary
Enlivex Therapeutics and Unusual Machines Inc. will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Enlivex Therapeutics, led by CEO Oren Hershkovitz, offers a promising investment opportunity in the biopharmaceutical sector with its innovative Allocetra™ cell therapy platform. The technology aims to reset immune cells for treating inflammatory and autoimmune diseases. On the other hand, Unusual Machines, under CEO Allan Evans, is focusing on the drone industry, acquiring valuable IP and brands to cater to various sectors. The company's subsidiaries, Fat Shark and Rotor Riot, are leading in FPV products and services, positioning Unusual Machines for long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) launches a new trial for AllocetraTM, a cell therapy to treat osteoarthritis in the knee. The therapy aims to reprogram macrophages and rebalance the immune microenvironment. The trial, authorized by the Israeli Ministry of Health, will evaluate efficacy, safety, and tolerability in up to 160 patients. This innovative approach could provide a new option for patients suffering from knee osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) is developing AllocetraTM, a cell therapy for sepsis treatment. The phase 2 trial of AllocetraTM has enrolled all 120 patients and is expected to release data by Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) has received a new patent, US 11,883,429, from the U.S. Patent and Trademark Office for its immunotherapy product candidate, AllocetraTM. The patent provides additional intellectual property protection for the product's composition and manufacturing method in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
none
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the authorization from the Israeli Ministry of Health for a multi-country Phase I/II trial to evaluate the efficacy, safety, and tolerability of Allocetra™ injections into the target knee joint of up to 160 moderately to severely symptomatic osteoarthritis patients. The trial will consist of a safety run-in, open-label dose escalation phase, followed by a double-blind, randomized, placebo-controlled stage. The primary measurements will assess joint-pain and joint-function compared to placebo at three months, six months, and 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) completes enrollment in Phase II trial for Allocetra™ in patients with sepsis. Topline data expected in late Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.96%
Tags
Rhea-AI Summary
Enlivex focuses on inflammatory and autoimmune indications, initiates clinical program in osteoarthritis, and plans to seek external collaborations for oncology assets. Workforce reduction of approximately 50% expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.73%
Tags

FAQ

What is the current stock price of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?

The current stock price of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) is $1.24 as of December 20, 2024.

What is the market cap of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?

The market cap of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) is approximately 25.8M.

What is Enlivex Therapeutics Ltd.?

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage immunotherapy company developing allogeneic drugs to rebalance the immune system.

What is Allocetra™?

Allocetra™ is Enlivex's flagship immunotherapy candidate, designed to reprogram macrophages and rebalance the immune system. It is being tested for severe sepsis, COVID-19, GVHD, and more.

What clinical trials are ongoing for Allocetra™?

Allocetra™ is in Phase IIB trials for severe sepsis, Phase II for COVID-19, and Phase IIA for GVHD prevention. Additionally, it's being tested in a Phase I/II trial for knee osteoarthritis.

What recent achievements has Enlivex made?

Enlivex received approval from the Israeli Ministry of Health for a new osteoarthritis trial and announced positive Phase II study results for Allocetra™ in sepsis patients.

What is the significance of Allocetra™ in osteoarthritis treatment?

Allocetra™ is being evaluated for its potential to reprogram macrophages and address the inflammatory causes of osteoarthritis, offering a novel treatment option.

How does Allocetra™ work?

Allocetra™ works by restoring macrophages to their homeostatic state, helping to rebalance the immune system and treat various severe and chronic conditions.

What are the benefits of Enlivex's therapy?

Enlivex's Allocetra™ offers a potential new mechanism of action for treating life-threatening and debilitating conditions by modulating the immune system.

What is the company's financial condition?

Enlivex recently closed a $5 million registered direct offering, indicating strong financial support for its ongoing and future clinical trials.

What are the future plans for Allocetra™?

Enlivex plans to continue expanding its clinical trials for Allocetra™, including potential larger studies for sepsis and ongoing trials for knee osteoarthritis.

Where can I find more information about Enlivex?

For more details, visit Enlivex's official website at http://www.enlivex.com.

Enlivex Therapeutics Ltd. Ordinary Shares

Nasdaq:ENLV

ENLV Rankings

ENLV Stock Data

25.77M
19.34M
5.74%
18.81%
0.46%
Biotechnology
Healthcare
Link
United States of America
Ness Ziona